Janssen Biotech, Inc. v. Celltrion Healthcare Co. Ltd. at al. (17-cv-11008).

Judge Wolf denied defendants 2019 motion to dismiss Janssen 2019s counterclaim of violation of 35 U.S.C. 00a7 271(f), finding that the counterclaim pled all of the necessary elements of such a claim. Janssen did not bring this claim in its original complaint, instead bringing it in its answer to the defendants 2019 counterclaim seeking a declaration of non-infringement and invalidity. Judge Wolf found the counterclaim to be of right to Janssen as a compulsory counterclaim, as opposed to an amended pleading that would require leave of court.